Upper GI & Pancreatobiliary Cancers

Upper GI & Pancreatobiliary Cancers represent a group of aggressive malignancies involving the esophagus, stomach, pancreas, liver, gallbladder, and biliary tract, and they remain a major cause of cancer-related morbidity and mortality worldwide. These cancers are often diagnosed at advanced stages due to vague early symptoms and limited screening strategies, making timely detection and effective management particularly challenging. Upper gastrointestinal cancers, including esophageal and gastric cancers, are closely associated with risk factors such as chronic gastroesophageal reflux disease, Helicobacter pylori infection, smoking, alcohol consumption, dietary habits, and genetic predisposition. Pancreatobiliary cancers—most notably pancreatic ductal adenocarcinoma and cholangiocarcinoma—are among the most lethal malignancies, characterized by rapid progression, early metastasis, and resistance to conventional therapies. Chronic pancreatitis, diabetes, obesity, primary sclerosing cholangitis, and biliary stone disease are recognized risk factors in this spectrum. Advances in diagnostic endoscopy, high-resolution imaging, endoscopic ultrasound, and molecular biomarkers have improved tumor detection, staging, and risk stratification. Multidisciplinary treatment approaches combining surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy are increasingly emphasized to optimize outcomes.